First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Subscribe To Our Newsletter & Stay Updated
